Ocular inflammatory events following COVID-19 vaccination: a multinational case series
| dc.creator | Ilaria Testi | |
| dc.creator | Carl Herbort | |
| dc.creator | Luca Cimino | |
| dc.creator | Salam Iriqat | |
| dc.creator | Jennifer e. Thorne | |
| dc.creator | Jose Echegaray | |
| dc.creator | Kalpana Babu | |
| dc.creator | Alexander Arthur Bialasiewicz | |
| dc.creator | Debra a. Goldstein | |
| dc.creator | Nima Ghadiri | |
| dc.creator | Alex Fonollosa Calduch | |
| dc.creator | Camilo Brandão-de-resende | |
| dc.creator | Gabriel Costa de Andrade | |
| dc.creator | Padmamalini Mahendradas | |
| dc.creator | Julio j. González-lópez | |
| dc.creator | Ester Carreño | |
| dc.creator | Rola n. Hamam | |
| dc.creator | Nicole Stübiger | |
| dc.creator | Bahram Bodaghi | |
| dc.creator | Yu-jang Chao | |
| dc.creator | Masaru Takeuchi | |
| dc.creator | Mei-ling Tay-kearney | |
| dc.creator | Rupesh Agrawal | |
| dc.creator | Alejandro Portero | |
| dc.creator | Hiroshi Keino | |
| dc.creator | Mar Esteban-ortega | |
| dc.creator | Joanna Prze'dziecka-do'yk | |
| dc.creator | Aleksandra Radosavljevi' | |
| dc.creator | Ian Paredes | |
| dc.creator | ho su Ling | |
| dc.creator | Wei Kiong | |
| dc.creator | Melissa Tien | |
| dc.creator | Carlos Pavesio | |
| dc.creator | Xin le ng | |
| dc.creator | Soon Phaik Chee | |
| dc.creator | Jay Siak | |
| dc.creator | Ines Hernanz-rodriguez | |
| dc.creator | Victor Menezo | |
| dc.creator | Christoph Tappeiner | |
| dc.creator | Franz Marie Cruz | |
| dc.creator | Peter Addison | |
| dc.creator | Laura Steeples | |
| dc.creator | Robert Kuijpers | |
| dc.creator | Daniel Vítor de Vasconcelos Santos | |
| dc.creator | Balini Balasubramaniam | |
| dc.creator | Peter Mccluskey | |
| dc.creator | Francesco Pichi | |
| dc.creator | Aniruddha Agarwal | |
| dc.date.accessioned | 2023-12-06T19:27:15Z | |
| dc.date.accessioned | 2025-09-08T23:18:25Z | |
| dc.date.available | 2023-12-06T19:27:15Z | |
| dc.date.issued | 2022 | |
| dc.format.mimetype | ||
| dc.identifier.doi | https://doi.org/10.1186/s12348-021-00275-x | |
| dc.identifier.issn | 1869-5760 | |
| dc.identifier.uri | https://hdl.handle.net/1843/61800 | |
| dc.language | eng | |
| dc.publisher | Universidade Federal de Minas Gerais | |
| dc.relation.ispartof | Journal of Ophthalmic Inflammation and Infection | |
| dc.rights | Acesso Aberto | |
| dc.subject | COVID-19 | |
| dc.subject | Vacinação | |
| dc.subject | SARS-CoV-2 | |
| dc.subject | Inflamação | |
| dc.subject | Uveíte | |
| dc.subject.other | Uveitis | |
| dc.subject.other | Ocular inflammation | |
| dc.subject.other | Immunomodulatory | |
| dc.subject.other | Coronavirus disease | |
| dc.subject.other | COVID-19 | |
| dc.subject.other | SARS-CoV-2 | |
| dc.subject.other | Vaccination | |
| dc.title | Ocular inflammatory events following COVID-19 vaccination: a multinational case series | |
| dc.type | Artigo de periódico | |
| local.citation.epage | 6 | |
| local.citation.issue | 4 | |
| local.citation.spage | 1 | |
| local.citation.volume | 12 | |
| local.description.resumo | Background Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions. Methods Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021. Results Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19–84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1–14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%). Conclusion Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome. | |
| local.identifier.orcid | https://orcid.org/0000-0002-6747-2024 | |
| local.publisher.country | Brasil | |
| local.publisher.department | MED - DEPARTAMENTO DE OFTALMOLOGIA E OTORRINOLARINGOLOGIA | |
| local.publisher.department | MEDICINA - FACULDADE DE MEDICINA | |
| local.publisher.initials | UFMG | |
| local.url.externa | https://joii-journal.springeropen.com/articles/10.1186/s12348-021-00275-x |
Arquivos
Pacote original
1 - 1 de 1
Carregando...
- Nome:
- Ocular inflammatory events following COVID-19 vaccination_ a multinational case series.pdf
- Tamanho:
- 192.2 KB
- Formato:
- Adobe Portable Document Format
Licença do pacote
1 - 1 de 1